SS-31 (Elamipretide) — PeptideReport.ai

Q: Is SS-31 (Elamipretide) FDA-approved?

Yes, but only in a narrow sense. As Forzinity®, elamipretide received FDA accelerated approval on September 19, 2025 solely to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. It is not approved for any other condition, including general "mitochondrial support," energy, or anti-aging use.

Q: What is Forzinity and what is it approved for?

Forzinity® is the FDA-approved brand name for elamipretide (SS-31), previously studied as Bendavia®. Its approval, granted under the accelerated pathway with a required postmarketing confirmatory trial, covers only muscle strength improvement in Barth syndrome, a rare genetic mitochondrial disease caused by TAZ gene mutations, in patients ≥30 kg. Continued marketing depends on a trial confirming that this muscle-strength surrogate translates into real clinical benefit.

Q: Is the "wellness" SS-31 sold by peptide vendors the same as the approved drug?

It is the same peptide sequence, but not the same regulated product. Research-chemical SS-31 sold for general wellness or longevity use is not manufactured to Forzinity®'s FDA-regulated standard, is not covered by its approved dosing or safety monitoring, and is used entirely off-label for purposes — like broad "mitochondrial optimization" — that FDA never reviewed. PeptideReport.ai does not provide dosing or self-administration guidance for this off-label use.

Q: What does the evidence show for SS-31 outside Barth syndrome?

Considerably less than wellness marketing often suggests. Dedicated Phase II/III trials of elamipretide in heart failure with reduced ejection fraction and in primary mitochondrial myopathy did not meet their primary endpoints, and earlier programs in ischemia-reperfusion injury and dry AMD were also discontinued. The only positive clinical signal supporting approval came from the TAZPOWER open-label extension in Barth syndrome specifically — Level I evidence for that population only, not evidence that generalizes to other uses.

Q: What is SS-31's history of prior trial failures?

SS-31/elamipretide has one of the longer development histories of any compound covered on this site — roughly 15 years — and it did not reach approval by a straightforward path. Multiple prior Phase II/III programs, including trials in heart failure and primary mitochondrial myopathy, failed to demonstrate significant benefit over placebo, and additional programs in ischemia-reperfusion injury and dry AMD were discontinued. The Barth syndrome approval followed this string of negative results in broader populations — context worth keeping in mind when weighing confident wellness-industry claims that SS-31 broadly "restores mitochondrial function."

Q: What are the safety concerns with SS-31/elamipretide?

On the approved Forzinity® label, the most common adverse reactions are injection site reactions (redness, pain, swelling, itching, bruising, or hives), typically managed with oral antihistamines or topical corticosteroids. Hypersensitivity, including anaphylaxis, is listed as a serious potential complication, and the formulation carries a benzyl alcohol toxicity risk specific to neonatal use. There is no boxed warning on the current label. Research-chemical SS-31 from peptide vendors carries additional, undefined risk because it falls outside this regulated manufacturing and monitoring framework — another reason PeptideReport.ai directs readers to a physician rather than offering self-administration guidance.

Mechanism of Action

The Cardiolipin-Binding Approach to Mitochondrial Function

SS-31's mechanism is distinctive among peptides on this site because its target is a phospholipid, not a receptor.

Inner Mitochondrial Membrane

Selective binding to cardiolipin

SS-31's alternating aromatic/cationic residue structure gives it high, selective affinity for cardiolipin, a phospholipid unique to the inner mitochondrial membrane that organizes electron transport chain (ETC) complexes into efficient "supercomplexes." Cardiolipin is prone to oxidative damage and peroxidation, which disorganizes ETC architecture — a process implicated in Barth syndrome (caused by mutations in the tafazzin gene, which is required for normal cardiolipin remodeling) and proposed, more speculatively, as a contributor to age-related mitochondrial decline generally.

Electron Transport Chain

Stabilized supercomplex organization, improved ATP synthesis efficiency, reduced electron leak

By stabilizing cardiolipin's structural role, SS-31 is proposed to preserve ETC supercomplex assembly, improving coupled ATP production and reducing the electron leak that generates reactive oxygen species (ROS) — the basis for its original antioxidant framing, though the FDA approval summary itself notes the mechanism may extend beyond simple antioxidant activity.

Clinical Evidence — A Long and Instructive Road

TAZPOWER and the Trials That Came Before It

SS-31/elamipretide has one of the longer and more checkered development histories of any compound on this site, which is itself a useful case study in how a molecule with real biological plausibility can take over a decade — and multiple negative trials — to find the specific population where it works.

TAZPOWER (Barth Syndrome)

Open-label extension; supported Forzinity® approval

Primary findingImproved knee extensor muscle strength from baseline

Approval basisAccelerated approval — surrogate/intermediate endpoint

Postmarketing requirementFDA required confirmatory trial verifying clinical benefit

Because this is an accelerated approval, continued marketing is contingent on a postmarketing trial confirming the muscle-strength surrogate translates to real-world clinical benefit.

Prior Programs — Not Successful

Multiple Phase II/III trials, 2010s–early 2020s

Heart failure (reduced EF)Did not meet primary endpoints

Primary mitochondrial myopathyFailed to demonstrate significant benefit vs. placebo

Ischemia-reperfusion / dry AMDEarlier programs also discontinued

The Barth syndrome approval followed roughly 15 years of drug development and several negative trials in broader mitochondrial-disease and cardiovascular populations — context that matters when interpreting confident wellness-industry claims that SS-31 broadly "restores mitochondrial function" across unrelated conditions.

FDA-Label Dosing (Barth Syndrome Only)

Approved Product Dosing — Not a General-Use Self-Administration Guide

The figures below are drawn from FDA-approved Forzinity® prescribing information, provided as factual product information for its one approved indication. This is not general dosing guidance for SS-31 used outside that indication, and PeptideReport.ai does not extend it to any off-label or research-chemical use.

Forzinity® — Standard Renal Function

40 mg SC once daily

Adults and pediatric patients ≥30 kg with Barth syndrome, per FDA label

Forzinity® — Renal Impairment

20 mg SC once daily

eGFR <30 mL/min, not on dialysis, per FDA label

Research-Chemical SS-31 Is a Different Risk Category

SS-31 sold by peptide vendors for general wellness/longevity use is not manufactured to Forzinity®'s FDA-regulated standard, is not covered by its approved dosing or safety monitoring, and is being used entirely off-label for conditions with a much thinner (largely preclinical) evidence base than Barth syndrome. PeptideReport.ai does not provide reconstitution or self-administration guidance for research-chemical SS-31.

Safety Profile

Approved-Label Safety Findings

Hypersensitivity, Including Anaphylaxis

Listed as a serious potential complication in the FDA label

Benzyl Alcohol Toxicity (Neonates)

Formulation-related risk specific to neonatal use, per label

Effect	Frequency / Notes
Injection site reactions (redness, pain, swelling, itching, bruising, hives)	Most common adverse reaction — typically managed with oral antihistamines or topical corticosteroids per label
Boxed warning	None on current Forzinity® label

Clinical Decision Tool

Candidate Framework

On-Label

Approved Candidate

✓Confirmed Barth syndrome diagnosis (TAZ gene mutation), patient weighing ≥30 kg

✓Under specialist (typically metabolic/genetic disease) physician management

Off-Label / Unapproved

Not an FDA-Reviewed Use

⚠General "mitochondrial support," energy, or anti-aging use — not the population or endpoint FDA reviewed

⚠Heart failure or mitochondrial myopathy outside Barth syndrome — prior dedicated trials in these populations did not succeed

⚠Sourcing from a peptide vendor rather than a licensed pharmacy dispensing Forzinity®

Comparator Context

SS-31 vs. Other Longevity/Mitochondrial Compounds

Compound	Mechanism Class	Regulatory Status	Evidence Basis
SS-31 (Elamipretide)	Cardiolipin-binding tetrapeptide	FDA-Approved (Barth syndrome only)	Level I for Barth syndrome; unapproved elsewhere
Epithalon	Telomerase-pathway pentapeptide	Not FDA-approved	Eastern-European Phase II/III — see Epithalon profile
NAD+	Redox coenzyme, IV infusion	Not FDA-approved	Small pilot/retrospective data only — see NAD+ profile

SS-31 is unusual in this comparison set: it has the strongest possible regulatory backing of the three, but only within an extremely narrow rare-disease population. Its broader wellness-market use rests on essentially the same preclinical/mechanistic reasoning as the other two compounds here, not on its approved trial data.

Common Questions

SS-31 / Elamipretide FAQ

Straightforward answers to the questions readers most often bring to this page, drawn directly from the approval history and evidence covered above.

Is SS-31 (Elamipretide) FDA-approved?

Yes, but only in a narrow sense. As Forzinity®, elamipretide received FDA accelerated approval on September 19, 2025 solely to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. It is not approved for any other condition, including general "mitochondrial support," energy, or anti-aging use.

What is Forzinity and what is it approved for?

Forzinity® is the FDA-approved brand name for elamipretide (SS-31), previously studied as Bendavia®. Its approval, granted under the accelerated pathway with a required postmarketing confirmatory trial, covers only muscle strength improvement in Barth syndrome, a rare genetic mitochondrial disease caused by TAZ gene mutations, in patients ≥30 kg. Continued marketing depends on a trial confirming that this muscle-strength surrogate translates into real clinical benefit.

Is the "wellness" SS-31 sold by peptide vendors the same as the approved drug?

It is the same peptide sequence, but not the same regulated product. Research-chemical SS-31 sold for general wellness or longevity use is not manufactured to Forzinity®'s FDA-regulated standard, is not covered by its approved dosing or safety monitoring, and is used entirely off-label for purposes — like broad "mitochondrial optimization" — that FDA never reviewed. PeptideReport.ai does not provide dosing or self-administration guidance for this off-label use.

What does the evidence show for SS-31 outside Barth syndrome?

Considerably less than wellness marketing often suggests. Dedicated Phase II/III trials of elamipretide in heart failure with reduced ejection fraction and in primary mitochondrial myopathy did not meet their primary endpoints, and earlier programs in ischemia-reperfusion injury and dry AMD were also discontinued. The only positive clinical signal supporting approval came from the TAZPOWER open-label extension in Barth syndrome specifically — Level I evidence for that population only, not evidence that generalizes to other uses.

What is SS-31's history of prior trial failures?

SS-31/elamipretide has one of the longer development histories of any compound covered on this site — roughly 15 years — and it did not reach approval by a straightforward path. Multiple prior Phase II/III programs, including trials in heart failure and primary mitochondrial myopathy, failed to demonstrate significant benefit over placebo, and additional programs in ischemia-reperfusion injury and dry AMD were discontinued. The Barth syndrome approval followed this string of negative results in broader populations — context worth keeping in mind when weighing confident wellness-industry claims that SS-31 broadly "restores mitochondrial function."

What are the safety concerns with SS-31/elamipretide?

On the approved Forzinity® label, the most common adverse reactions are injection site reactions (redness, pain, swelling, itching, bruising, or hives), typically managed with oral antihistamines or topical corticosteroids. Hypersensitivity, including anaphylaxis, is listed as a serious potential complication, and the formulation carries a benzyl alcohol toxicity risk specific to neonatal use. There is no boxed warning on the current label. Research-chemical SS-31 from peptide vendors carries additional, undefined risk because it falls outside this regulated manufacturing and monitoring framework — another reason PeptideReport.ai directs readers to a physician rather than offering self-administration guidance.

Physician Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. SS-31's story — a genuine FDA approval for one rare disease, sitting alongside a much larger unregulated wellness market for the same molecule — is exactly the kind of nuance PeptideReport.ai was founded to explain clearly rather than blur together.